Matthen Mathew

Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors

Shoiab Bukhari, Brian S. Henick, Robert Winchester et al. · Cell Reports Medicine · 2022 · 71 citations · Full text

Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion

Xun Wu, Yi‐Shing Lisa Cheng, Matthen Mathew et al. · Journal of Experimental & Clinical Cancer Research · 2021 · 61 citations · Full text

Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)

Danny Rischin, Stefanie L. Groenland, Annette M. Lim et al. · Annals of Oncology · 2019 · 19 citations · Full text

Induce-1 Expansion Cohorts, Cancer Immunosurveillance, Medicine +11

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).

Eric Angevin, Stefanie L. Groenland, Annette M. Lim et al. · Journal of Clinical Oncology · 2020 · 17 citations

Anti-pd-1/l1 Treatment-naïve Head, Immunodeficiencies, Immunology +22

Characteristics and outcomes of lung cancer in solid organ transplant recipients

Lanyi Nora Chen, John Spivack, Thu Cao et al. · Lung Cancer · 2020 · 14 citations

Lung Transplantation, Transplantation, Medicine +7